PHA-680632, a novel aurora kinase inhibitor with potent antitumoral activity

Chiara Soncini, Patrizia Carpinelli, Laura Gianellini, Daniele Fancelli, Paola Vianello, Luisa Rusconi, Paola Storici, Paola Zugnoni, Enrico Pesenti, Valter Croci, Roberta Ceruti, Maria Laura Giorgini, Paolo Cappella, Dario Ballinari, Francesco Sola, Mario Varasi, Rodrigo Bravo, Jürgen Moll

Research output: Contribution to journalArticle

143 Citations (Scopus)

Abstract

Purpose: Aurora kinases play critical roles during mitosis in chromosome segregation and cell division. The aim of this study was to determine the preclinical profile of a novel, highly selective Aurora kinase inhibitor, PHA-680632, as a candidate for anticancer therapy. Experimental Design: The activity of PHA-680632 was assayed in a biochemical ATP competitive kinase assay. A wide panel of cell lines was evaluated for antiproliferative activity. Cell cycle analysis. Immunohistochemistry, Western blotting, and Array Scan were used to follow mechanism of action and biomarker modulation. Specific knockdown of the targets by small interfering RNA was followed to validate the observed phenotypes. Efficacy was determined in different xenograft models and in a transgenic animal model of breast cancer. Results: PHA-680632 is active on a wide range of cancer cell lines and shows significant tumor growth inhibition in different animal tumor models at well-tolerated doses. The mechanism of action of PHA-680632 is in agreement with inhibition of Aurora kinases. Histone H3 phosphorylation in Ser10 is mediated by Aurora B kinase, and our kinetic studies on its inhibition by PHA-680632 in vitro and in vivo show that phosphorylation of histone H3 is a good biomarker to follow activity of PHA-680632. Conclusions: PHA-680632 is the first representative of a new class of Aurora inhibitors with a high potential for further development as an anticancer therapeutic. On treatment, different cell lines respond differentially, suggesting the absence of critical cell cycle checkpoints that could be the basis for a favorable therapeutic window.

Original languageEnglish
Pages (from-to)4080-4089
Number of pages10
JournalClinical Cancer Research
Volume12
Issue number13
DOIs
Publication statusPublished - Jul 1 2006

Fingerprint

Aurora Kinases
Cell Line
Histones
Animal Models
Aurora Kinase B
Biomarkers
Phosphorylation
Neoplasms
Chromosome Segregation
Genetically Modified Animals
Therapeutics
Cell Cycle Checkpoints
PHA 680632
Mitosis
Heterografts
Cell Division
Small Interfering RNA
Cell Cycle
Research Design
Phosphotransferases

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Soncini, C., Carpinelli, P., Gianellini, L., Fancelli, D., Vianello, P., Rusconi, L., ... Moll, J. (2006). PHA-680632, a novel aurora kinase inhibitor with potent antitumoral activity. Clinical Cancer Research, 12(13), 4080-4089. https://doi.org/10.1158/1078-0432.CCR-05-1964

PHA-680632, a novel aurora kinase inhibitor with potent antitumoral activity. / Soncini, Chiara; Carpinelli, Patrizia; Gianellini, Laura; Fancelli, Daniele; Vianello, Paola; Rusconi, Luisa; Storici, Paola; Zugnoni, Paola; Pesenti, Enrico; Croci, Valter; Ceruti, Roberta; Giorgini, Maria Laura; Cappella, Paolo; Ballinari, Dario; Sola, Francesco; Varasi, Mario; Bravo, Rodrigo; Moll, Jürgen.

In: Clinical Cancer Research, Vol. 12, No. 13, 01.07.2006, p. 4080-4089.

Research output: Contribution to journalArticle

Soncini, C, Carpinelli, P, Gianellini, L, Fancelli, D, Vianello, P, Rusconi, L, Storici, P, Zugnoni, P, Pesenti, E, Croci, V, Ceruti, R, Giorgini, ML, Cappella, P, Ballinari, D, Sola, F, Varasi, M, Bravo, R & Moll, J 2006, 'PHA-680632, a novel aurora kinase inhibitor with potent antitumoral activity', Clinical Cancer Research, vol. 12, no. 13, pp. 4080-4089. https://doi.org/10.1158/1078-0432.CCR-05-1964
Soncini C, Carpinelli P, Gianellini L, Fancelli D, Vianello P, Rusconi L et al. PHA-680632, a novel aurora kinase inhibitor with potent antitumoral activity. Clinical Cancer Research. 2006 Jul 1;12(13):4080-4089. https://doi.org/10.1158/1078-0432.CCR-05-1964
Soncini, Chiara ; Carpinelli, Patrizia ; Gianellini, Laura ; Fancelli, Daniele ; Vianello, Paola ; Rusconi, Luisa ; Storici, Paola ; Zugnoni, Paola ; Pesenti, Enrico ; Croci, Valter ; Ceruti, Roberta ; Giorgini, Maria Laura ; Cappella, Paolo ; Ballinari, Dario ; Sola, Francesco ; Varasi, Mario ; Bravo, Rodrigo ; Moll, Jürgen. / PHA-680632, a novel aurora kinase inhibitor with potent antitumoral activity. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 13. pp. 4080-4089.
@article{4b93500c854a443aa376765eb36356a8,
title = "PHA-680632, a novel aurora kinase inhibitor with potent antitumoral activity",
abstract = "Purpose: Aurora kinases play critical roles during mitosis in chromosome segregation and cell division. The aim of this study was to determine the preclinical profile of a novel, highly selective Aurora kinase inhibitor, PHA-680632, as a candidate for anticancer therapy. Experimental Design: The activity of PHA-680632 was assayed in a biochemical ATP competitive kinase assay. A wide panel of cell lines was evaluated for antiproliferative activity. Cell cycle analysis. Immunohistochemistry, Western blotting, and Array Scan were used to follow mechanism of action and biomarker modulation. Specific knockdown of the targets by small interfering RNA was followed to validate the observed phenotypes. Efficacy was determined in different xenograft models and in a transgenic animal model of breast cancer. Results: PHA-680632 is active on a wide range of cancer cell lines and shows significant tumor growth inhibition in different animal tumor models at well-tolerated doses. The mechanism of action of PHA-680632 is in agreement with inhibition of Aurora kinases. Histone H3 phosphorylation in Ser10 is mediated by Aurora B kinase, and our kinetic studies on its inhibition by PHA-680632 in vitro and in vivo show that phosphorylation of histone H3 is a good biomarker to follow activity of PHA-680632. Conclusions: PHA-680632 is the first representative of a new class of Aurora inhibitors with a high potential for further development as an anticancer therapeutic. On treatment, different cell lines respond differentially, suggesting the absence of critical cell cycle checkpoints that could be the basis for a favorable therapeutic window.",
author = "Chiara Soncini and Patrizia Carpinelli and Laura Gianellini and Daniele Fancelli and Paola Vianello and Luisa Rusconi and Paola Storici and Paola Zugnoni and Enrico Pesenti and Valter Croci and Roberta Ceruti and Giorgini, {Maria Laura} and Paolo Cappella and Dario Ballinari and Francesco Sola and Mario Varasi and Rodrigo Bravo and J{\"u}rgen Moll",
year = "2006",
month = "7",
day = "1",
doi = "10.1158/1078-0432.CCR-05-1964",
language = "English",
volume = "12",
pages = "4080--4089",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - PHA-680632, a novel aurora kinase inhibitor with potent antitumoral activity

AU - Soncini, Chiara

AU - Carpinelli, Patrizia

AU - Gianellini, Laura

AU - Fancelli, Daniele

AU - Vianello, Paola

AU - Rusconi, Luisa

AU - Storici, Paola

AU - Zugnoni, Paola

AU - Pesenti, Enrico

AU - Croci, Valter

AU - Ceruti, Roberta

AU - Giorgini, Maria Laura

AU - Cappella, Paolo

AU - Ballinari, Dario

AU - Sola, Francesco

AU - Varasi, Mario

AU - Bravo, Rodrigo

AU - Moll, Jürgen

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Purpose: Aurora kinases play critical roles during mitosis in chromosome segregation and cell division. The aim of this study was to determine the preclinical profile of a novel, highly selective Aurora kinase inhibitor, PHA-680632, as a candidate for anticancer therapy. Experimental Design: The activity of PHA-680632 was assayed in a biochemical ATP competitive kinase assay. A wide panel of cell lines was evaluated for antiproliferative activity. Cell cycle analysis. Immunohistochemistry, Western blotting, and Array Scan were used to follow mechanism of action and biomarker modulation. Specific knockdown of the targets by small interfering RNA was followed to validate the observed phenotypes. Efficacy was determined in different xenograft models and in a transgenic animal model of breast cancer. Results: PHA-680632 is active on a wide range of cancer cell lines and shows significant tumor growth inhibition in different animal tumor models at well-tolerated doses. The mechanism of action of PHA-680632 is in agreement with inhibition of Aurora kinases. Histone H3 phosphorylation in Ser10 is mediated by Aurora B kinase, and our kinetic studies on its inhibition by PHA-680632 in vitro and in vivo show that phosphorylation of histone H3 is a good biomarker to follow activity of PHA-680632. Conclusions: PHA-680632 is the first representative of a new class of Aurora inhibitors with a high potential for further development as an anticancer therapeutic. On treatment, different cell lines respond differentially, suggesting the absence of critical cell cycle checkpoints that could be the basis for a favorable therapeutic window.

AB - Purpose: Aurora kinases play critical roles during mitosis in chromosome segregation and cell division. The aim of this study was to determine the preclinical profile of a novel, highly selective Aurora kinase inhibitor, PHA-680632, as a candidate for anticancer therapy. Experimental Design: The activity of PHA-680632 was assayed in a biochemical ATP competitive kinase assay. A wide panel of cell lines was evaluated for antiproliferative activity. Cell cycle analysis. Immunohistochemistry, Western blotting, and Array Scan were used to follow mechanism of action and biomarker modulation. Specific knockdown of the targets by small interfering RNA was followed to validate the observed phenotypes. Efficacy was determined in different xenograft models and in a transgenic animal model of breast cancer. Results: PHA-680632 is active on a wide range of cancer cell lines and shows significant tumor growth inhibition in different animal tumor models at well-tolerated doses. The mechanism of action of PHA-680632 is in agreement with inhibition of Aurora kinases. Histone H3 phosphorylation in Ser10 is mediated by Aurora B kinase, and our kinetic studies on its inhibition by PHA-680632 in vitro and in vivo show that phosphorylation of histone H3 is a good biomarker to follow activity of PHA-680632. Conclusions: PHA-680632 is the first representative of a new class of Aurora inhibitors with a high potential for further development as an anticancer therapeutic. On treatment, different cell lines respond differentially, suggesting the absence of critical cell cycle checkpoints that could be the basis for a favorable therapeutic window.

UR - http://www.scopus.com/inward/record.url?scp=33746080016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746080016&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-1964

DO - 10.1158/1078-0432.CCR-05-1964

M3 - Article

C2 - 16818708

AN - SCOPUS:33746080016

VL - 12

SP - 4080

EP - 4089

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 13

ER -